APIMEDS PHARMACEUTICALS US, INC. Accretion Expense
APIMEDS PHARMACEUTICALS US, INC. (APUS) reported Accretion Expense of $8.39 thousand for the 3-month period ending 2026-03-31, per its 10-Q filed 2026-05-26.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:AccretionExpense · last filed 2026-05-26
- APIMEDS PHARMACEUTICALS US, INC. accretion expense for the quarter ending 2026-03-31 was $8.39K, a 25.49% decline year-over-year.
- APIMEDS PHARMACEUTICALS US, INC. accretion expense for the quarter ending 2025-12-31 was $243.18K, a 288.35% increase year-over-year.
- APIMEDS PHARMACEUTICALS US, INC. accretion expense for the quarter ending 2025-09-30 was $1.00, a 100.00% decline year-over-year.
- APIMEDS PHARMACEUTICALS US, INC. accretion expense for the quarter ending 2025-06-30 was $28.58K, a 109.82% increase year-over-year.
- APIMEDS PHARMACEUTICALS US, INC. accretion expense for fiscal 2025 was $283.01K, a 140.41% increase from fiscal 2024.
- APIMEDS PHARMACEUTICALS US, INC. accretion expense for fiscal 2024 was $117.72K, a 2222.33% increase from fiscal 2023.
- APIMEDS PHARMACEUTICALS US, INC. accretion expense for fiscal 2023 was $5.07K.
| Period end | Accretion Expense 3 month | Accretion Expense 3 month as first filed | Accretion Expense 6 month | Accretion Expense 9 month | Accretion Expense 12 month | Accretion Expense 12 month as first filed |
|---|---|---|---|---|---|---|
| 2026-03-31 | $8.39K 10-Q · filed 2026-05-26 | $251.56K derived: sum of 2 quarters · filed 2026-05-26 | $251.56K derived: sum of 3 quarters · filed 2026-05-26 | $280.14K derived: sum of 4 quarters · filed 2026-05-26 | ||
| 2025-12-31 | $243.18K derived: 10-K 12 month − 10-Q 9 month · filed 2026-05-04 | $243.18K derived: sum of 2 quarters · filed 2026-05-04 | $271.75K derived: sum of 3 quarters · filed 2026-05-04 | $283.01K 10-K · filed 2026-05-04 | ||
| 2025-09-30 | $1.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $28.58K derived: sum of 2 quarters · filed 2025-11-12 | $39.83K 10-Q · filed 2025-11-12 | $102.45K derived: sum of 4 quarters · filed 2026-05-26 | ||
| 2025-06-30 | $28.58K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-19 | $39.83K 10-Q · filed 2025-08-19 | $102.45K derived: sum of 3 quarters · filed 2026-05-26 | $124.98K derived: sum of 4 quarters · filed 2026-05-26 | ||
| 2025-03-31 | $11.26K 10-Q · filed 2026-05-26 | $26.78K 10-Q · filed 2025-05-20 | $73.87K derived: sum of 2 quarters · filed 2026-05-26 | $96.40K derived: sum of 3 quarters · filed 2026-05-26 | $110.02K derived: sum of 4 quarters · filed 2026-05-26 | |
| 2024-12-31 | $62.62K derived: 10-K 12 month − 10-Q 9 month · filed 2026-05-04 | $85.15K derived: sum of 2 quarters · filed 2026-05-04 | $98.77K derived: sum of 3 quarters · filed 2026-05-04 | $117.72K 10-K · filed 2026-05-04 | $79.95K 10-K · filed 2025-04-15 | |
| 2024-09-30 | $22.53K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $36.15K derived: sum of 2 quarters · filed 2025-11-12 | $55.10K 10-Q · filed 2025-11-12 | |||
| 2024-06-30 | $13.62K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-19 | $32.57K 10-Q · filed 2025-08-19 | ||||
| 2024-03-31 | $18.95K 10-Q · filed 2025-05-20 | |||||
| 2023-12-31 | $5.07K 10-K · filed 2025-04-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |